Xandra Owens Breakefield - Publications

Affiliations: 
Harvard Medical School/ MGH, Boston, MA, United States 
Area:
Neurogenetics, Gene Therapy
Website:
http://www.massgeneral.org/breakefieldlab/

291 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Hanlon KS, Kleinstiver BP, Garcia SP, Zaborowski MP, Volak A, Spirig SE, Muller A, Sousa AA, Tsai SQ, Bengtsson NE, Lööv C, Ingelsson M, Chamberlain JS, Corey DP, Aryee MJ, ... ... Breakefield XO, et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nature Communications. 10: 4439. PMID 31570731 DOI: 10.1038/s41467-019-12449-2  0.52
2019 Prabhakar S, Cheah PS, Zhang X, Zinter M, Gianatasio M, Hudry E, Bronson RT, Kwiatkowski DJ, Stemmer-Rachamimov A, Maguire CA, Sena-Esteves M, Tannous BA, Breakefield XO. Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Molecular Therapy. Methods & Clinical Development. 15: 18-26. PMID 31534984 DOI: 10.1016/j.omtm.2019.08.003  0.52
2019 Abels ER, Maas SLN, Nieland L, Wei Z, Cheah PS, Tai E, Kolsteeg CJ, Dusoswa SA, Ting DT, Hickman S, El Khoury J, Krichevsky AM, Broekman MLD, Breakefield XO. Glioblastoma-Associated Microglia Reprogramming Is Mediated by Functional Transfer of Extracellular miR-21. Cell Reports. 28: 3105-3119.e7. PMID 31533034 DOI: 10.1016/j.celrep.2019.08.036  0.44
2019 Abels ER, Broekman MLD, Breakefield XO, Maas SLN. Glioma EVs Contribute to Immune Privilege in the Brain. Trends in Cancer. 5: 393-396. PMID 31311653 DOI: 10.1016/j.trecan.2019.05.006  0.44
2019 Srinivasan S, Yeri A, Cheah PS, Chung A, Danielson K, De Hoff P, Filant J, Laurent CD, Laurent LD, Magee R, Moeller C, Murthy VL, Nejad P, Paul A, Rigoutsos I, ... ... Breakefield XO, et al. Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation. Cell. 177: 446-462.e16. PMID 30951671 DOI: 10.1016/j.cell.2019.03.024  0.52
2018 Gustafsson G, Lööv C, Persson E, Lázaro DF, Takeda S, Bergström J, Erlandsson A, Sehlin D, Balaj L, György B, Hallbeck M, Outeiro TF, Breakefield XO, Hyman BT, Ingelsson M. Secretion and Uptake of α-Synuclein Via Extracellular Vesicles in Cultured Cells. Cellular and Molecular Neurobiology. PMID 30288631 DOI: 10.1007/s10571-018-0622-5  0.52
2018 Antoury L, Hu N, Balaj L, Das S, Georghiou S, Darras B, Clark T, Breakefield XO, Wheeler TM. Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nature Communications. 9: 3906. PMID 30254196 DOI: 10.1038/s41467-018-06206-0  0.52
2018 György B, Lööv C, Zaborowski MP, Takeda S, Kleinstiver BP, Commins C, Kastanenka K, Mu D, Volak A, Giedraitis V, Lannfelt L, Maguire CA, Joung JK, Hyman BT, Breakefield XO, et al. CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. Molecular Therapy. Nucleic Acids. 11: 429-440. PMID 29858078 DOI: 10.1016/j.omtn.2018.03.007  0.52
2018 Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, Rooj AK, Krasemann S, Carter BS, Chen CC, Steed T, ... ... Breakefield XO, et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Science Advances. 4: eaar2766. PMID 29532035 DOI: 10.1126/sciadv.aar2766  0.52
2018 Aneichyk T, Hendriks WT, Yadav R, Shin D, Gao D, Vaine CA, Collins RL, Domingo A, Currall B, Stortchevoi A, Multhaupt-Buell T, Penney EB, Cruz L, Dhakal J, Brand H, ... ... Breakefield XO, et al. Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. Cell. 172: 897-909.e21. PMID 29474918 DOI: 10.1016/j.cell.2018.02.011  0.56
2018 Reátegui E, van der Vos KE, Lai CP, Zeinali M, Atai NA, Aldikacti B, Floyd FP, H Khankhel A, Thapar V, Hochberg FH, Sequist LV, Nahed BV, S Carter B, Toner M, Balaj L, ... ... Breakefield XO, et al. Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nature Communications. 9: 175. PMID 29330365 DOI: 10.1038/s41467-017-02261-1  0.52
2018 Lee K, Fraser K, Ghaddar B, Yang K, Kim E, Balaj L, Chiocca EA, Breakefield XO, Lee H, Weissleder R. Multiplexed Profiling of Single Extracellular Vesicles. Acs Nano. PMID 29286635 DOI: 10.1021/acsnano.7b07060  0.52
2017 Bragg DC, Mangkalaphiban K, Vaine CA, Kulkarni NJ, Shin D, Yadav R, Dhakal J, Ton ML, Cheng A, Russo CT, Ang M, Acuña P, Go C, Franceour TN, Multhaupt-Buell T, ... ... Breakefield XO, et al. Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1. Proceedings of the National Academy of Sciences of the United States of America. PMID 29229810 DOI: 10.1073/pnas.1712526114  0.56
2017 Wei Z, Batagov AO, Schinelli S, Wang J, Wang Y, El Fatimy R, Rabinovsky R, Balaj L, Chen CC, Hochberg F, Carter B, Breakefield XO, Krichevsky AM. Coding and noncoding landscape of extracellular RNA released by human glioma stem cells. Nature Communications. 8: 1145. PMID 29074968 DOI: 10.1038/s41467-017-01196-x  0.52
2017 György B, Sage C, Indzhykulian AA, Scheffer DI, Brisson AR, Tan S, Wu X, Volak A, Mu D, Tamvakologos PI, Li Y, Fitzpatrick Z, Ericsson M, Breakefield XO, Corey DP, et al. Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using Exosome-Associated AAV. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28082074 DOI: 10.1016/j.ymthe.2016.12.010  0.52
2016 Soares VY, Atai NA, Fujita T, Dilwali S, Sivaraman S, Landegger LD, Hochberg FH, Oliveira CA, Bahmad F, Breakefield XO, Stankovic KM. Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells. Neuro-Oncology. PMID 27194145 DOI: 10.1093/neuonc/now099  0.52
2016 Zappulli V, Friis KP, Fitzpatrick Z, Maguire CA, Breakefield XO. Extracellular vesicles and intercellular communication within the nervous system. The Journal of Clinical Investigation. 126: 1198-207. PMID 27035811 DOI: 10.1172/JCI81134  0.52
2016 Hall J, Prabhakar S, Balaj L, Lai CP, Cerione RA, Breakefield XO. Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson's Disease, Glioma, and Schwannoma. Cellular and Molecular Neurobiology. PMID 27017608 DOI: 10.1007/s10571-015-0309-0  0.96
2016 Ricklefs F, Mineo M, Rooj AK, Nakano I, Charest A, Weissleder R, Breakefield XO, Chiocca EA, Godlewski J, Bronisz A. Extracellular vesicles from high grade glioma exchange diverse pro-oncogenic signals that maintain intratumoral heterogeneity. Cancer Research. PMID 27013191 DOI: 10.1158/0008-5472.CAN-15-3432  0.96
2016 Lööv C, Scherzer CR, Hyman BT, Breakefield XO, Ingelsson M. α-Synuclein in Extracellular Vesicles: Functional Implications and Diagnostic Opportunities. Cellular and Molecular Neurobiology. PMID 26993503 DOI: 10.1007/s10571-015-0317-0  0.96
2016 Pucci F, Garris C, Lai CP, Newton A, Pfirschke C, Engblom C, Alvarez D, Sprachman M, Evavold C, Magnuson A, von Andrian UH, Glatz K, Breakefield XO, Mempel TR, Weissleder R, et al. SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science (New York, N.Y.). PMID 26989197 DOI: 10.1126/science.aaf1328  0.96
2016 Zhang X, Abels ER, Redzic JS, Margulis J, Finkbeiner S, Breakefield XO. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture. Cellular and Molecular Neurobiology. PMID 26951563 DOI: 10.1007/s10571-016-0350-7  0.96
2016 Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. PMID 26905292 DOI: 10.1016/j.neuropharm.2016.02.013  0.96
2016 Ito N, Hendriks WT, Dhakal J, Vaine CA, Liu C, Shin D, Shin K, Wakabayashi-Ito N, Dy M, Multhaupt-Buell T, Sharma N, Breakefield XO, Bragg DC. Decreased N-TAF1 expression in X-Linked Dystonia-Parkinsonism patient-specific neural stem cells. Disease Models & Mechanisms. PMID 26769797 DOI: 10.1242/dmm.022590  0.96
2015 Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study. Bioscience. 65: 783-797. PMID 26955082 DOI: 10.1093/biosci/biv084  0.52
2015 van der Vos KE, Abels ER, Zhang X, Lai C, Carrizosa E, Oakley D, Prabhakar S, Mardini O, Crommentuijn MH, Skog J, Krichevsky AM, Stemmer-Rachamimov A, Mempel TR, El Khoury J, Hickman SE, ... Breakefield XO, et al. Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro-Oncology. PMID 26433199 DOI: 10.1093/neuonc/nov244  0.96
2015 Prabhakar S, Zhang X, Goto J, Han S, Lai C, Bronson R, Sena-Esteves M, Ramesh V, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiology of Disease. 82: 22-31. PMID 26019056 DOI: 10.1016/j.nbd.2015.04.018  0.96
2015 Balaj L, Atai NA, Chen W, Mu D, Tannous BA, Breakefield XO, Skog J, Maguire CA. Heparin affinity purification of extracellular vesicles. Scientific Reports. 5: 10266. PMID 25988257 DOI: 10.1038/srep10266  0.96
2015 Lai CP, Kim EY, Badr CE, Weissleder R, Mempel TR, Tannous BA, Breakefield XO. Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nature Communications. 6: 7029. PMID 25967391 DOI: 10.1038/ncomms8029  0.96
2015 Shao H, Chung J, Lee K, Balaj L, Min C, Carter BS, Hochberg FH, Breakefield XO, Lee H, Weissleder R. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Nature Communications. 6: 6999. PMID 25959588 DOI: 10.1038/ncomms7999  0.96
2015 Wakabayashi-Ito N, Ajjuri RR, Henderson BW, Doherty OM, Breakefield XO, O'Donnell JM, Ito N. Mutant human torsinA, responsible for early-onset dystonia, dominantly suppresses GTPCH expression, dopamine levels and locomotion in Drosophila melanogaster. Biology Open. 4: 585-95. PMID 25887123 DOI: 10.1242/bio.201411080  0.96
2015 Gong Y, Mu D, Prabhakar S, Moser A, Musolino P, Ren J, Breakefield XO, Maguire CA, Eichler FS. Adenoassociated virus serotype 9-mediated gene therapy for x-linked adrenoleukodystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 824-34. PMID 25592337 DOI: 10.1038/mt.2015.6  0.96
2015 György B, Hung ME, Breakefield XO, Leonard JN. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annual Review of Pharmacology and Toxicology. 55: 439-64. PMID 25292428 DOI: 10.1146/annurev-pharmtox-010814-124630  0.96
2015 Nery FC, da Hora CC, Yaqub U, Zhang X, McCarthy DM, Bhide PG, Irimia D, Breakefield XO. New methods for investigation of neuronal migration in embryonic brain explants. Journal of Neuroscience Methods. 239: 80-4. PMID 25291524 DOI: 10.1016/j.jneumeth.2014.09.028  0.96
2015 Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular Vesicles: Composition, Biological Relevance, and Methods of Study Bioscience. 65: 783-797. DOI: 10.1093/biosci/biv084  0.96
2015 Chadwick LH, Sawa A, Yang IV, Baccarelli A, Breakefield XO, Deng HW, Dolinoy DC, Fallin MD, Holland NT, Houseman EA, Lomvardas S, Rao M, Satterlee JS, Tyson FL, Vijayanand P, et al. New insights and updated guidelines for epigenome-wide association studies Neuroepigenetics. 1: 14-19. DOI: 10.1016/j.nepig.2014.10.004  0.96
2014 Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, et al. Update from the 2013 International Neurofibromatosis Conference. American Journal of Medical Genetics. Part A. 164: 2969-78. PMID 25255738 DOI: 10.1002/ajmg.a.36754  0.96
2014 Maguire CA, Ramirez SH, Merkel SF, Sena-Esteves M, Breakefield XO. Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 817-39. PMID 25159276 DOI: 10.1007/s13311-014-0299-5  0.96
2014 Hettich J, Ryan SD, de Souza ON, Saraiva Macedo Timmers LF, Tsai S, Atai NA, da Hora CC, Zhang X, Kothary R, Snapp E, Ericsson M, Grundmann K, Breakefield XO, Nery FC. Biochemical and cellular analysis of human variants of the DYT1 dystonia protein, TorsinA/TOR1A. Human Mutation. 35: 1101-13. PMID 24930953 DOI: 10.1002/humu.22602  0.96
2014 Nery FC, da Hora CC, Atai NA, Kim EY, Hettich J, Mempel TR, Breakefield XO, Irimia D. Microfluidic platform to evaluate migration of cells from patients with DYT1 dystonia. Journal of Neuroscience Methods. 232: 181-8. PMID 24880044 DOI: 10.1016/j.jneumeth.2014.05.027  0.96
2014 Redzic JS, Balaj L, van der Vos KE, Breakefield XO. Extracellular RNA mediates and marks cancer progression. Seminars in Cancer Biology. 28: 14-23. PMID 24783980 DOI: 10.1016/j.semcancer.2014.04.010  0.96
2014 Vader P, Breakefield XO, Wood MJ. Extracellular vesicles: emerging targets for cancer therapy. Trends in Molecular Medicine. 20: 385-93. PMID 24703619 DOI: 10.1016/j.molmed.2014.03.002  0.96
2014 Lai CP, Mardini O, Ericsson M, Prabhakar S, Maguire CA, Chen JW, Tannous BA, Breakefield XO. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. Acs Nano. 8: 483-94. PMID 24383518 DOI: 10.1021/nn404945r  0.96
2014 Lai CP, Tannous BA, Breakefield XO. Noninvasive in vivo monitoring of extracellular vesicles. Methods in Molecular Biology (Clifton, N.J.). 1098: 249-58. PMID 24166382 DOI: 10.1007/978-1-62703-718-1_19  0.96
2013 Akers JC, Ramakrishnan V, Kim R, Skog J, Nakano I, Pingle S, Kalinina J, Hua W, Kesari S, Mao Y, Breakefield XO, Hochberg FH, Van Meir EG, Carter BS, Chen CC. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. Plos One. 8: e78115. PMID 24205116 DOI: 10.1371/journal.pone.0078115  0.96
2013 Armata IA, Balaj L, Kuster JK, Zhang X, Tsai S, Armatas AA, Multhaupt-Buell TJ, Soberman R, Breakefield XO, Ichinose H, Sharma N. Dopa-responsive dystonia: functional analysis of single nucleotide substitutions within the 5' untranslated GCH1 region. Plos One. 8: e76975. PMID 24124602 DOI: 10.1371/journal.pone.0076975  0.96
2013 Atai NA, Balaj L, van Veen H, Breakefield XO, Jarzyna PA, Van Noorden CJ, Skog J, Maguire CA. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. Journal of Neuro-Oncology. 115: 343-51. PMID 24002181 DOI: 10.1007/s11060-013-1235-y  0.96
2013 Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, Loguidice L, Soto H, Garrett M, Zhu LD, Sivaraman S, Chen C, Wong ET, Carter BS, Hochberg FH, ... Breakefield XO, et al. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Molecular Therapy. Nucleic Acids. 2: e109. PMID 23881452 DOI: 10.1038/mtna.2013.28  0.96
2013 Prabhakar S, Goto J, Zhang X, Zuang X, Sena-Esteves M, Bronson R, Brockmann J, Gianni D, Wojtkiewicz GR, Chen JW, Stemmer-Rachamimov A, Kwiatkowski DJ, Breakefield XO. Stochastic model of Tsc1 lesions in mouse brain. Plos One. 8: e64224. PMID 23696872 DOI: 10.1371/journal.pone.0064224  0.96
2013 EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nature Reviews. Drug Discovery. 12: 347-57. PMID 23584393 DOI: 10.1038/nrd3978  0.96
2013 Prabhakar S, Taherian M, Gianni D, Conlon TJ, Fulci G, Brockmann J, Stemmer-Rachamimov A, Sena-Esteves M, Breakefield XO, Brenner GJ. Regression of schwannomas induced by adeno-associated virus-mediated delivery of caspase-1. Human Gene Therapy. 24: 152-62. PMID 23140466 DOI: 10.1089/hum.2012.094  0.96
2013 Mizrak A, Bolukbasi MF, Ozdener GB, Brenner GJ, Madlener S, Erkan EP, Ströbel T, Breakefield XO, Saydam O. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 101-8. PMID 22910294 DOI: 10.1038/mt.2012.161  0.96
2012 Bolukbasi MF, Mizrak A, Ozdener GB, Madlener S, Ströbel T, Erkan EP, Fan JB, Breakefield XO, Saydam O. miR-1289 and "Zipcode"-like Sequence Enrich mRNAs in Microvesicles. Molecular Therapy. Nucleic Acids. 1: e10. PMID 23344721 DOI: 10.1038/mtna.2011.2  0.96
2012 Kalra H, Simpson RJ, Ji H, Aikawa E, Altevogt P, Askenase P, Bond VC, Borràs FE, Breakefield X, Budnik V, Buzas E, Camussi G, Clayton A, Cocucci E, Falcon-Perez JM, et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. Plos Biology. 10: e1001450. PMID 23271954 DOI: 10.1371/journal.pbio.1001450  0.96
2012 Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS, Hochberg FH, Breakefield XO, Weissleder R, Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nature Medicine. 18: 1835-40. PMID 23142818 DOI: 10.1038/nm.2994  0.96
2012 Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakefield XO, Pegtel DM. Extracellular vesicles and their convergence with viral pathways. Advances in Virology. 2012: 767694. PMID 22888349 DOI: 10.1155/2012/767694  0.96
2012 Breakefield XO. Refocus the recombinant DNA advisory committee. Nature Medicine. 18: 1007. PMID 22772546 DOI: 10.1038/nm0712-1007  0.96
2012 Lai CP, Breakefield XO. Role of exosomes/microvesicles in the nervous system and use in emerging therapies. Frontiers in Physiology. 3: 228. PMID 22754538 DOI: 10.3389/fphys.2012.00228  0.96
2012 Atai NA, Ryan SD, Kothary R, Breakefield XO, Nery FC. Untethering the nuclear envelope and cytoskeleton: biologically distinct dystonias arising from a common cellular dysfunction. International Journal of Cell Biology. 2012: 634214. PMID 22611399 DOI: 10.1155/2012/634214  0.96
2012 Maguire CA, Balaj L, Sivaraman S, Crommentuijn MH, Ericsson M, Mincheva-Nilsson L, Baranov V, Gianni D, Tannous BA, Sena-Esteves M, Breakefield XO, Skog J. Microvesicle-associated AAV vector as a novel gene delivery system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 960-71. PMID 22314290 DOI: 10.1038/mt.2011.303  0.96
2012 Noerholm M, Balaj L, Limperg T, Salehi A, Zhu LD, Hochberg FH, Breakefield XO, Carter BS, Skog J. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. Bmc Cancer. 12: 22. PMID 22251860 DOI: 10.1186/1471-2407-12-22  0.96
2012 Breakefield XO. The ASGCT in 2012: Charting a path to bring novel biologic therapies to the clinic Molecular Therapy. 20: 1289. DOI: 10.1038/mt.2012.122  0.96
2011 Wakabayashi-Ito N, Doherty OM, Moriyama H, Breakefield XO, Gusella JF, O'Donnell JM, Ito N. Dtorsin, the Drosophila ortholog of the early-onset dystonia TOR1A (DYT1), plays a novel role in dopamine metabolism. Plos One. 6: e26183. PMID 22022556 DOI: 10.1371/journal.pone.0026183  0.96
2011 Pike LS, Tannous BA, Deliolanis NC, Hsich G, Morse D, Tung CH, Sena-Esteves M, Breakefield XO. Imaging gene delivery in a mouse model of congenital neuronal ceroid lipofuscinosis. Gene Therapy. 18: 1173-8. PMID 21900963 DOI: 10.1038/gt.2011.118  0.96
2011 Breakefield XO, Frederickson RM, Simpson RJ. Gesicles: Microvesicle "cookies" for transient information transfer between cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1574-6. PMID 21886114 DOI: 10.1038/mt.2011.169  0.96
2011 Nery FC, Armata IA, Farley JE, Cho JA, Yaqub U, Chen P, da Hora CC, Wang Q, Tagaya M, Klein C, Tannous B, Caldwell KA, Caldwell GA, Lencer WI, Ye Y, ... Breakefield XO, et al. TorsinA participates in endoplasmic reticulum-associated degradation. Nature Communications. 2: 393. PMID 21750546 DOI: 10.1038/ncomms1383  0.96
2011 van der Vos KE, Balaj L, Skog J, Breakefield XO. Brain tumor microvesicles: insights into intercellular communication in the nervous system. Cellular and Molecular Neurobiology. 31: 949-59. PMID 21553248 DOI: 10.1007/s10571-011-9697-y  0.96
2011 Deliolanis NC, Wurdinger T, Pike L, Tannous BA, Breakefield XO, Weissleder R, Ntziachristos V. In vivo tomographic imaging of red-shifted fluorescent proteins. Biomedical Optics Express. 2: 887-900. PMID 21483611 DOI: 10.1364/BOE.2.000887  0.96
2011 Erkan EP, Breakefield XO, Saydam O. miRNA signature of schwannomas: possible role(s) of "tumor suppressor" miRNAs in benign tumors. Oncotarget. 2: 265-70. PMID 21454924  0.96
2011 Bowers WJ, Breakefield XO, Sena-Esteves M. Genetic therapy for the nervous system. Human Molecular Genetics. 20: R28-41. PMID 21429918 DOI: 10.1093/hmg/ddr110  0.96
2011 Smits M, Mir SE, Nilsson RJ, van der Stoop PM, Niers JM, Marquez VE, Cloos J, Breakefield XO, Krichevsky AM, Noske DP, Tannous BA, Würdinger T. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. Plos One. 6: e16282. PMID 21297974 DOI: 10.1371/journal.pone.0016282  0.96
2011 Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nature Communications. 2: 180. PMID 21285958 DOI: 10.1038/ncomms1180  0.96
2011 Saydam O, Senol O, Würdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, Yi M, Stephens RM, Krichevsky AM, Saydam N, Brenner GJ, Breakefield XO. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Research. 71: 852-61. PMID 21156648 DOI: 10.1158/0008-5472.CAN-10-1219  0.96
2011 Bragg DC, Armata IA, Nery FC, Breakefield XO, Sharma N. Molecular pathways in dystonia. Neurobiology of Disease. 42: 136-47. PMID 21134457 DOI: 10.1016/j.nbd.2010.11.015  0.96
2011 Saydam O, Ozdener GB, Senol O, Mizrak A, Prabhakar S, Stemmer-Rachamimov AO, Breakefield XO, Brenner GJ. A novel imaging-compatible sciatic nerve schwannoma model. Journal of Neuroscience Methods. 195: 75-7. PMID 21111000 DOI: 10.1016/j.jneumeth.2010.10.021  0.96
2010 Breakefield XO, Sena-Esteves M. Healing genes in the nervous system. Neuron. 68: 178-81. PMID 20955923 DOI: 10.1016/j.neuron.2010.10.005  0.96
2010 Chen P, Burdette AJ, Porter JC, Ricketts JC, Fox SA, Nery FC, Hewett JW, Berkowitz LA, Breakefield XO, Caldwell KA, Caldwell GA. The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Human Molecular Genetics. 19: 3502-15. PMID 20584926 DOI: 10.1093/hmg/ddq266  0.96
2010 Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Therapy. 17: 655-63. PMID 20508670 DOI: 10.1038/cgt.2010.22  0.96
2010 Cao S, Hewett JW, Yokoi F, Lu J, Buckley AC, Burdette AJ, Chen P, Nery FC, Li Y, Breakefield XO, Caldwell GA, Caldwell KA. Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. Disease Models & Mechanisms. 3: 386-96. PMID 20223934 DOI: 10.1242/dmm.003715  0.96
2010 Chen C, Skog J, Hsu CH, Lessard RT, Balaj L, Wurdinger T, Carter BS, Breakefield XO, Toner M, Irimia D. Microfluidic isolation and transcriptome analysis of serum microvesicles. Lab On a Chip. 10: 505-11. PMID 20126692 DOI: 10.1039/b916199f  0.96
2010 Prabhakar S, Brenner GJ, Sung B, Messerli SM, Mao J, Sena-Esteves M, Stemmer-Rachamimov A, Tannous B, Breakefield XO. Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Therapy. 17: 266-74. PMID 19834516 DOI: 10.1038/cgt.2009.71  0.96
2010 Breakefield XO, Standaert DG. Torsion Dystonia Encyclopedia of Neuroscience. 1029-1034. DOI: 10.1016/B978-008045046-9.01507-2  0.96
2009 Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Molecular and Cellular Biology. 29: 5923-40. PMID 19703993 DOI: 10.1128/MCB.00332-09  0.96
2009 Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. British Journal of Cancer. 100: 1603-7. PMID 19401683 DOI: 10.1038/sj.bjc.6605058  0.96
2009 Tannous BA, Christensen AP, Pike L, Wurdinger T, Perry KF, Saydam O, Jacobs AH, García-Añoveros J, Weissleder R, Sena-Esteves M, Corey DP, Breakefield XO. Mutant sodium channel for tumor therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 810-9. PMID 19259066 DOI: 10.1038/mt.2009.33  0.96
2009 Tannous BA, Chiocca EA, Jacobs AH, Corey DP, Breakefield XO. Tannous et al. Respond: Molecular Therapy. 17: 1311-1312. DOI: 10.1038/mt.2009.166  0.96
2008 Jinnah H, Richter A, Mink JW, Caldwell GA, Caldwell KA, Gonzalez-Alegre P, Cookson MR, Breakefield XO, Delong MR, Hess EJ. Animal models for drug discovery in dystonia. Expert Opinion On Drug Discovery. 3: 83-97. PMID 23480141 DOI: 10.1517/17460441.3.1.83  0.96
2008 Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT, Carter BS, Krichevsky AM, Breakefield XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nature Cell Biology. 10: 1470-6. PMID 19011622 DOI: 10.1038/ncb1800  0.96
2008 Würdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, Weissleder R, Breakefield XO, Krichevsky AM. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 14: 382-93. PMID 18977327 DOI: 10.1016/j.ccr.2008.10.005  0.96
2008 Nery FC, Zeng J, Niland BP, Hewett J, Farley J, Irimia D, Li Y, Wiche G, Sonnenberg A, Breakefield XO. TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. Journal of Cell Science. 121: 3476-86. PMID 18827015 DOI: 10.1242/jcs.029454  0.96
2008 Maguire CA, Meijer DH, LeRoy SG, Tierney LA, Broekman ML, Costa FF, Breakefield XO, Stemmer-Rachamimov A, Sena-Esteves M. Preventing growth of brain tumors by creating a zone of resistance. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1695-702. PMID 18714312 DOI: 10.1038/mt.2008.168  0.96
2008 Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R. Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model Journal of Neuroscience. 28: 4406-4413. PMID 18434519 DOI: 10.1523/JNEUROSCI.0296-08.2008  0.96
2008 Schubert M, Breakefield X, Federoff H, Frederickson RM, Lowenstein PR. Gene delivery to the nervous system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 640-6. PMID 18362921 DOI: 10.1038/mt.2008.42  0.96
2008 de Oliveira AP, Glauser DL, Laimbacher AS, Strasser R, Schraner EM, Wild P, Ziegler U, Breakefield XO, Ackermann M, Fraefel C. Live visualization of herpes simplex virus type 1 compartment dynamics. Journal of Virology. 82: 4974-90. PMID 18337577 DOI: 10.1128/JVI.02431-07  0.96
2008 Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. Nature Reviews. Neuroscience. 9: 222-34. PMID 18285800 DOI: 10.1038/nrn2337  0.96
2008 Hewett JW, Nery FC, Niland B, Ge P, Tan P, Hadwiger P, Tannous BA, Sah DW, Breakefield XO. siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells. Human Molecular Genetics. 17: 1436-45. PMID 18258738 DOI: 10.1093/hmg/ddn032  0.96
2008 Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO, Tannous BA. A secreted luciferase for ex vivo monitoring of in vivo processes. Nature Methods. 5: 171-3. PMID 18204457 DOI: 10.1038/nmeth.1177  0.96
2008 Cortés ML, Oehmig A, Saydam O, Sanford JD, Perry KF, Fraefel C, Breakefield XO. Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 81-8. PMID 17998902 DOI: 10.1038/sj.mt.6300338  0.96
2008 Kamm C, Ozelius LJ, Breakefield XO. TorsinA and DYT1 early-onset dystonia Future Neurology. 3: 61-72. DOI: 10.2217/14796708.3.1.61  0.96
2007 Badr CE, Hewett JW, Breakefield XO, Tannous BA. A highly sensitive assay for monitoring the secretory pathway and ER stress. Plos One. 2: e571. PMID 17593970 DOI: 10.1371/journal.pone.0000571  0.96
2007 Balcioglu A, Kim MO, Sharma N, Cha JH, Breakefield XO, Standaert DG. Dopamine release is impaired in a mouse model of DYT1 dystonia. Journal of Neurochemistry. 102: 783-8. PMID 17550429 DOI: 10.1111/j.1471-4159.2007.04590.x  0.96
2007 Jeong KH, Bakowska JC, Song IO, Fu N, Breakefield XO, Kaiser UB. Improvement in reproductive parameters in hypogonadal female mice by regulated gene replacement therapy in the central nervous system. Gene Therapy. 14: 1092-101. PMID 17476303 DOI: 10.1038/sj.gt.3302957  0.96
2007 Oehmig A, Cortés ML, Perry KF, Sena-Esteves M, Fraefel C, Breakefield XO. Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector. Gene Therapy. 14: 1078-91. PMID 17460718 DOI: 10.1038/sj.gt.3302960  0.96
2007 Hewett JW, Tannous B, Niland BP, Nery FC, Zeng J, Li Y, Breakefield XO. Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proceedings of the National Academy of Sciences of the United States of America. 104: 7271-6. PMID 17428918 DOI: 10.1073/pnas.0701185104  0.96
2007 Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Therapy. 14: 460-7. PMID 17304235 DOI: 10.1038/sj.cgt.7701037  0.96
2006 Bahn E, Siegert S, Pfander T, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostásy KM. TorsinB expression in the developing human brain. Brain Research. 1116: 112-9. PMID 16938275 DOI: 10.1016/j.brainres.2006.07.102  0.96
2006 Cortés ML, Oehmig A, Perry KF, Sanford JD, Breakefield XO. Expression of human ATM cDNA in Atm-deficient mouse brain mediated by HSV-1 amplicon vector. Neuroscience. 141: 1247-56. PMID 16809004 DOI: 10.1016/j.neuroscience.2006.05.055  0.96
2006 Shah K, Breakefield XO. HSV amplicon vectors for cancer therapy. Current Gene Therapy. 6: 361-70. PMID 16787187 DOI: 10.2174/156652306777592063  0.96
2006 Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Metabolic biotinylation of cell surface receptors for in vivo imaging. Nature Methods. 3: 391-6. PMID 16628210 DOI: 10.1038/nmeth875  0.96
2006 Kock N, Naismith TV, Boston HE, Ozelius LJ, Corey DP, Breakefield XO, Hanson PI. Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier. Human Molecular Genetics. 15: 1355-64. PMID 16537570 DOI: 10.1093/hmg/ddl055  0.96
2006 McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Research. 66: 2509-13. PMID 16510565 DOI: 10.1158/0008-5472.CAN-05-2242  0.96
2006 Vasudevan A, Breakefield XO, Bhide PG. Developmental patterns of torsinA and torsinB expression. Brain Research. 1073: 139-45. PMID 16458269 DOI: 10.1016/j.brainres.2005.12.087  0.96
2006 Messerli SM, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R, Bronson R, Martuza R, Rabkin S, Breakefield XO. Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Human Gene Therapy. 17: 20-30. PMID 16409122 DOI: 10.1089/hum.2006.17.20  0.96
2006 Hewett JW, Zeng J, Niland BP, Bragg DC, Breakefield XO. Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiology of Disease. 22: 98-111. PMID 16361107 DOI: 10.1016/j.nbd.2005.10.012  0.96
2006 Kock N, Allchorne AJ, Sena-Esteves M, Woolf CJ, Breakefield XO. RNAi blocks DYT1 mutant torsinA inclusions in neurons. Neuroscience Letters. 395: 201-5. PMID 16332410 DOI: 10.1016/j.neulet.2005.10.098  0.96
2006 Senn C, Fraefel C, Breakefield XO. HSV Amplicon Vectors for Gene Delivery to the Nervous System Gene Therapy of the Central Nervous System: From Bench to Bedside. 25-43. DOI: 10.1016/B978-012397632-1/50004-6  0.96
2005 Brown AB, Mahmood U, Cortes ML, Tang Y, Dai G, Stemmer-Rachamimov A, Prabhakar S, Leishear K, Onda H, Kwiatkowski D, Weissleder R, Breakefield X. Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous sclerosis as a model for endothelial cell-based transgene delivery Human Gene Therapy. 16: 1367-1376. PMID 16390268 DOI: 10.1089/hum.2005.16.1367  0.96
2005 Siegert S, Bahn E, Kramer ML, Schulz-Schaeffer WJ, Hewett JW, Breakefield XO, Hedreen JC, Rostasy KM. TorsinA expression is detectable in human infants as young as 4 weeks old. Brain Research. Developmental Brain Research. 157: 19-26. PMID 15939081 DOI: 10.1016/j.devbrainres.2005.02.019  0.96
2005 Sharma N, Baxter MG, Petravicz J, Bragg DC, Schienda A, Standaert DG, Breakefield XO. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 5351-5. PMID 15930383 DOI: 10.1523/JNEUROSCI.0855-05.2005  0.96
2005 Shah K, Tung CH, Breakefield XO, Weissleder R. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 926-31. PMID 15922963 DOI: 10.1016/j.ymthe.2005.01.017  0.96
2005 Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 435-43. PMID 15727940 DOI: 10.1016/j.ymthe.2004.10.016  0.96
2005 Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R, Breakefield XO. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Annals of Neurology. 57: 34-41. PMID 15622535 DOI: 10.1002/ana.20306  0.96
2005 Sharma N, Cristopher Bragg D, Petravicz J, Standaert DG, Breakefield XO. DYT1 transgenic mouse Movement Disorders. 287-292. DOI: 10.1016/B978-012088382-0/50024-4  0.96
2004 Shah K, Hsich G, Breakefield XO. Neural precursor cells and their role in neuro-oncology. Developmental Neuroscience. 26: 118-30. PMID 15711055 DOI: 10.1159/000082132  0.96
2004 Oehmig A, Fraefel C, Breakefield XO, Ackermann M. Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus. Current Gene Therapy. 4: 385-408. PMID 15578989  0.96
2004 Bragg DC, Kaufman CA, Kock N, Breakefield XO. Inhibition of N-linked glycosylation prevents inclusion formation by the dystonia-related mutant form of torsinA. Molecular and Cellular Neurosciences. 27: 417-26. PMID 15555920 DOI: 10.1016/j.mcn.2004.07.009  0.96
2004 Oehmig A, Fraefel C, Breakefield XO. Update on herpesvirus amplicon vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 630-43. PMID 15451447 DOI: 10.1016/j.ymthe.2004.06.641  0.96
2004 Kamm C, Leung J, Joseph S, Dobyns WB, Brashear A, Breakefield XO, Ozelius LJ. Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 845-7. PMID 15254951 DOI: 10.1002/mds.20095  0.96
2004 Hewett JW, Kamm C, Boston H, Beauchamp R, Naismith T, Ozelius L, Hanson PI, Breakefield XO, Ramesh V. TorsinB--perinuclear location and association with torsinA. Journal of Neurochemistry. 89: 1186-94. PMID 15147511 DOI: 10.1111/j.1471-4159.2004.02404.x  0.96
2004 Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Therapy. 11: 1175-87. PMID 15141158 DOI: 10.1038/sj.gt.3302278  0.96
2004 Messerli SM, Prabhakar S, Tang Y, Shah K, Cortes ML, Murthy V, Weissleder R, Breakefield XO, Tung CH. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia (New York, N.Y.). 6: 95-105. PMID 15140398 DOI: 10.1593/neo.03214  0.96
2004 Naismith TV, Heuser JE, Breakefield XO, Hanson PI. TorsinA in the nuclear envelope. Proceedings of the National Academy of Sciences of the United States of America. 101: 7612-7. PMID 15136718 DOI: 10.1073/pnas.0308760101  0.96
2004 Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Research. 64: 3236-42. PMID 15126365 DOI: 10.1158/0008-5472.CAN-03-3516  0.96
2004 Grandi P, Spear M, Breakefield XO, Wang S. Targeting HSV amplicon vectors. Methods (San Diego, Calif.). 33: 179-86. PMID 15121173 DOI: 10.1016/j.ymeth.2003.11.007  0.96
2004 Bragg DC, Camp SM, Kaufman CA, Wilbur JD, Boston H, Schuback DE, Hanson PI, Sena-Esteves M, Breakefield XO. Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors. Neuroscience. 125: 651-61. PMID 15099679 DOI: 10.1016/j.neuroscience.2004.01.053  0.96
2004 Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, ... ... Breakefield XO, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics. 74: 1064-73. PMID 15060842 DOI: 10.1086/420795  0.96
2004 Bagley J, Cortes ML, Breakefield XO, Iacomini J. Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice. Blood. 104: 572-8. PMID 15044255 DOI: 10.1182/blood-2003-12-4226  0.96
2004 Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO. HSV-1 virions engineered for specific binding to cell surface receptors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 419-27. PMID 15006609 DOI: 10.1016/j.ymthe.2003.12.010  0.96
2004 Kamm C, Boston H, Hewett J, Wilbur J, Corey DP, Hanson PI, Ramesh V, Breakefield XO. The early onset dystonia protein torsinA interacts with kinesin light chain 1. The Journal of Biological Chemistry. 279: 19882-92. PMID 14970196 DOI: 10.1074/jbc.M401332200  0.96
2004 Kabakci K, Hedrich K, Leung JC, Mitterer M, Vieregge P, Lencer R, Hagenah J, Garrels J, Witt K, Klostermann F, Svetel M, Friedman J, Kostic V, Bressman SB, Breakefield XO, et al. Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology. 62: 395-400. PMID 14872019  0.96
2004 Shah K, Tung CH, Chang CH, Slootweg E, O'Loughlin T, Breakefield XO, Weissleder R. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Research. 64: 273-8. PMID 14729634 DOI: 10.1158/0008-5472.CAN-03-1123  0.96
2004 Bragg DC, Slater DJ, Breakefield XO. TorsinA and early-onset torsion dystonia. Advances in Neurology. 94: 87-93. PMID 14509659  0.96
2004 Augood SJ, Hollingsworth Z, Albers DS, Yang L, Leung J, Breakefield XO, Standaert DG. Dopamine transmission in DYT1 dystonia. Advances in Neurology. 94: 53-60. PMID 14509654  0.96
2003 Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, Black PM, Breakefield XO, Aboody KS. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Human Gene Therapy. 14: 1777-85. PMID 14670128 DOI: 10.1089/104303403322611782  0.96
2003 Yoshimura S, Teramoto T, Whalen MJ, Irizarry MC, Takagi Y, Qiu J, Harada J, Waeber C, Breakefield XO, Moskowitz MA. FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice. The Journal of Clinical Investigation. 112: 1202-10. PMID 14561705 DOI: 10.1172/JCI16618  0.96
2003 Augood SJ, Keller-McGandy CE, Siriani A, Hewett J, Ramesh V, Sapp E, DiFiglia M, Breakefield XO, Standaert DG. Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain. Brain Research. 986: 12-21. PMID 12965225 DOI: 10.1016/S0006-8993(03)03164-0  0.96
2003 Bakowska JC, Di Maria MV, Camp SM, Wang Y, Allen PD, Breakefield XO. Targeted transgene integration into transgenic mouse fibroblasts carrying the full-length human AAVS1 locus mediated by HSV/AAV rep(+) hybrid amplicon vector. Gene Therapy. 10: 1691-702. PMID 12923568 DOI: 10.1038/sj.gt.3302061  0.96
2003 Cortés ML, Bakkenist CJ, Di Maria MV, Kastan MB, Breakefield XO. HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype. Gene Therapy. 10: 1321-7. PMID 12883528 DOI: 10.1038/sj.gt.3301996  0.96
2003 Hampl JA, Camp SM, Mydlarz WK, Hampl M, Ichikawa T, Chiocca EA, Louis DN, Sena-Esteves M, Breakefield XO. Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Human Gene Therapy. 14: 611-26. PMID 12804144 DOI: 10.1089/104303403321618137  0.96
2003 Wang S, Petravicz J, Breakefield XO. Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system. Molecular Therapy : the Journal of the American Society of Gene Therapy. 7: 790-800. PMID 12788653 DOI: 10.1016/S1525-0016(03)00094-7  0.96
2003 Simon DK, Friedman J, Breakefield XO, Jankovic J, Brin MF, Provias J, Bressman SB, Charness ME, Tarsy D, Johns DR, Tarnopolsky MA. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 4: 199-205. PMID 12756609 DOI: 10.1007/s10048-003-0150-3  0.96
2003 Davidson BL, Breakefield XO. Viral vectors for gene delivery to the nervous system. Nature Reviews. Neuroscience. 4: 353-64. PMID 12728263 DOI: 10.1038/nrn1104  0.96
2003 Hewett J, Ziefer P, Bergeron D, Naismith T, Boston H, Slater D, Wilbur J, Schuback D, Kamm C, Smith N, Camp S, Ozelius LJ, Ramesh V, Hanson PI, Breakefield XO. TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. Journal of Neuroscience Research. 72: 158-68. PMID 12671990 DOI: 10.1002/jnr.10567  0.96
2003 Rostasy K, Augood SJ, Hewett JW, Leung JC, Sasaki H, Ozelius LJ, Ramesh V, Standaert DG, Breakefield XO, Hedreen JC. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiology of Disease. 12: 11-24. PMID 12609485 DOI: 10.1016/S0969-9961(02)00010-4  0.96
2003 Saeki Y, Breakefield XO, Chiocca EA. Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods in Molecular Medicine. 76: 51-60. PMID 12526158  0.96
2003 Spear MA, Schuback D, Miyata K, Grandi P, Sun F, Yoo L, Nguyen A, Brandt CR, Breakefield XO. HSV-1 amplicon peptide display vector. Journal of Virological Methods. 107: 71-9. PMID 12445940 DOI: 10.1016/S0166-0934(02)00193-3  0.96
2002 Lam P, Hui KM, Wang Y, Allen PD, Louis DN, Yuan CJ, Breakefield XO. Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors. Human Gene Therapy. 13: 2147-59. PMID 12542846 DOI: 10.1089/104303402320987842  0.96
2002 Sandler VM, Wang S, Angelo K, Lo HG, Breakefield XO, Clapham DE. Modified herpes simplex virus delivery of enhanced GFP into the central nervous system. Journal of Neuroscience Methods. 121: 211-9. PMID 12468010 DOI: 10.1016/S0165-0270(02)00262-5  0.96
2002 McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, Ueda K, Breakefield XO, Hyman BT. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. Journal of Neurochemistry. 83: 846-54. PMID 12421356 DOI: 10.1046/j.1471-4159.2002.01190.x  0.96
2002 Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO. Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia (New York, N.Y.). 4: 501-9. PMID 12407444 DOI: 10.1038/sj.neo.7900265  0.96
2002 Klein C, Liu L, Doheny D, Kock N, Müller B, de Carvalho Aguiar P, Leung J, de Leon D, Bressman SB, Silverman J, Smith C, Danisi F, Morrison C, Walker RH, Velickovic M, ... ... Breakefield XO, et al. Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations. Annals of Neurology. 52: 675-9. PMID 12402271 DOI: 10.1002/ana.10358  0.96
2002 Doheny D, Danisi F, Smith C, Morrison C, Velickovic M, De Leon D, Bressman SB, Leung J, Ozelius L, Klein C, Breakefield XO, Brin MF, Silverman JM. Clinical findings of a myoclonus-dystonia family with two distinct mutations. Neurology. 59: 1244-6. PMID 12391355  0.96
2002 Pal PK, Leung J, Hedrich K, Samii A, Lieberman A, Nausieda PA, Calne DB, Breakefield XO, Klein C, Stoessl AJ. [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 789-94. PMID 12210877 DOI: 10.1002/mds.10133  0.96
2002 Augood SJ, Hollingsworth Z, Albers DS, Yang L, Leung JC, Muller B, Klein C, Breakefield XO, Standaert DG. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology. 59: 445-8. PMID 12177384  0.96
2002 Sena-Esteves M, Hampl JA, Camp SM, Breakefield XO. Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors. The Journal of Gene Medicine. 4: 229-39. PMID 12112640 DOI: 10.1002/jgm.276  0.96
2002 Kann M, Jacobs H, Mohrmann K, Schumacher K, Hedrich K, Garrels J, Wiegers K, Schwinger E, Pramstaller PP, Breakefield XO, Ozelius LJ, Vieregge P, Klein C. Role of parkin mutations in 111 community-based patients with early-onset parkinsonism. Annals of Neurology. 51: 621-5. PMID 12112109 DOI: 10.1002/ana.10179  0.96
2002 Wang Y, Camp SM, Niwano M, Shen X, Bakowska JC, Breakefield XO, Allen PD. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. Journal of Virology. 76: 7150-62. PMID 12072515 DOI: 10.1128/JVI.76.14.7150-7162.2002  0.96
2002 Ziefer P, Leung J, Razzano T, Shalish C, LeDoux MS, Lorden JF, Ozelius L, Breakefield XO, Standaert DG, Augood SJ. Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat. Brain Research. Molecular Brain Research. 101: 132-5. PMID 12007841 DOI: 10.1016/S0169-328X(02)00176-6  0.96
2002 Costantini LC, Fraefel C, Breakefield XO, Isacson O. Herpes simplex virus/adeno-associated virus hybrid vectors for gene transfer to neurons. Preparation and use. Methods in Molecular Medicine. 69: 461-79. PMID 11987795  0.96
2002 Pramstaller PP, Kis B, Eskelson C, Hedrich K, Scherer M, Schwinger E, Breakefield XO, Kramer PL, Ozelius LJ, Klein C. Phenotypic variability in a large kindred (Family LA) with deletions in the parkin gene. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 424-6. PMID 11921141 DOI: 10.1002/mds.10071  0.96
2002 Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, Ozelius L. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 339-45. PMID 11921121 DOI: 10.1002/mds.10096  0.96
2002 Hsich G, Sena-Esteves M, Breakefield XO. Critical issues in gene therapy for neurologic disease. Human Gene Therapy. 13: 579-604. PMID 11916483 DOI: 10.1089/10430340252837198  0.96
2002 Wang Y, Mukherjee S, Fraefel C, Breakefield XO, Allen PD. Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. Human Gene Therapy. 13: 261-73. PMID 11812282 DOI: 10.1089/10430340252769789  0.96
2002 Aguilar-Cordova CE, Macklin R, Markert ML, Mickelson CA, Ando DG, Breakefield XO, Friedmann TC, Gordon JW, Greenblatt JJ, Juengst ET, King NMP, Levi-Pearl SL. U.S. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee: Minutes of meeting: December 6, 2001 Human Gene Therapy. 13: 1663-1673. DOI: 10.1089/10430340260201752  0.96
2001 Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, DeLeon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, ... ... Breakefield XO, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics. 3: 133-43. PMID 11523564 DOI: 10.1007/s100480100111  0.96
2001 Spear MA, Breakefield XO, Beltzer J, Schuback D, Weissleder R, Pardo FS, Ladner R. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Therapy. 8: 506-11. PMID 11498772 DOI: 10.1038/sj.cgt.7700334  0.96
2001 Breakefield XO, Kamm C, Hanson PI. TorsinA: movement at many levels. Neuron. 31: 9-12. PMID 11498045 DOI: 10.1016/S0896-6273(01)00350-6  0.96
2001 Hedrich K, Kann M, Lanthaler AJ, Dalski A, Eskelson C, Landt O, Schwinger E, Vieregge P, Lang AE, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Human Molecular Genetics. 10: 1649-56. PMID 11487568  0.96
2001 Sharma N, Hewett J, Ozelius LJ, Ramesh V, McLean PJ, Breakefield XO, Hyman BT. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. The American Journal of Pathology. 159: 339-44. PMID 11438481  0.96
2001 Yoshimura S, Takagi Y, Harada J, Teramoto T, Thomas SS, Waeber C, Bakowska JC, Breakefield XO, Moskowitz MA. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proceedings of the National Academy of Sciences of the United States of America. 98: 5874-9. PMID 11320217 DOI: 10.1073/pnas.101034998  0.96
2001 Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Molecular Therapy : the Journal of the American Society of Gene Therapy. 3: 591-601. PMID 11319922 DOI: 10.1006/mthe.2001.0294  0.96
2001 Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Research. 61: 2983-95. PMID 11306477  0.96
2001 Lam PY, Breakefield XO. Potential of gene therapy for brain tumors. Human Molecular Genetics. 10: 777-87. PMID 11257112  0.96
2000 McIvor RS, Ando D, Breakefield XO, Buckley R, Chow L, Deisseroth A, Greenblatt J, Mickelson C. Prenatal gene transfer: Scientific, medical, and ethical issues: A report of the recombinant DNA advisory committee Human Gene Therapy. 11: 1211-1229. PMID 11660775 DOI: 10.1089/10430340050015257  0.96
2000 Lam PY, Breakefield XO. Hybrid vector designs to control the delivery, fate and expression of transgenes. The Journal of Gene Medicine. 2: 395-408. PMID 11199260 DOI: 10.1002/1521-2254(200011/12)2:6<395::AID-JGM146>3.0.CO;2-K  0.96
2000 Friedman JR, Klein C, Leung J, Woodward H, Ozelius LJ, Breakefield XO, Charness ME. The GAG deletion of the DYT1 gene is infrequent in musicians with focal dystonia. Neurology. 55: 1417-8. PMID 11087801  0.96
2000 Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Therapy. 7: 1648-55. PMID 11083473 DOI: 10.1038/sj.gt.3301272  0.96
2000 Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, Breakefield XO, Snyder EY. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proceedings of the National Academy of Sciences of the United States of America. 97: 12846-51. PMID 11070094 DOI: 10.1073/pnas.97.23.12846  0.96
2000 Fraefel C, Jacoby DR, Breakefield XO. Herpes simplex virus type 1-based amplicon vector systems. Advances in Virus Research. 55: 425-51. PMID 11050950  0.96
2000 Estuardo Aguilar-Cordova C, Levi-Pearl SL, Macklin R, Markert ML, McIvor RS, Mickelson CA, Wolff JA, Ando DG, Breakefield XO, Chow LT, Friedmann T, Gordon JW, Greenblatt JJ, Juengst ET, King NMP. Department of health and human services national institutes of health recombinant DNA advisory committee: Minutes of meeting March 8-10, 2000 Human Gene Therapy. 11: 2159-2192. PMID 11044916 DOI: 10.1089/104303400750001453  0.96
2000 Klein C, Schilling K, Saunders-Pullman RJ, Garrels J, Breakefield XO, Brin MF, deLeon D, Doheny D, Fahn S, Fink JS, Forsgren L, Friedman J, Frucht S, Harris J, Holmgren G, et al. A major locus for myoclonus-dystonia maps to chromosome 7q in eight families. American Journal of Human Genetics. 67: 1314-9. PMID 11022010  0.96
2000 Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY, Breakefield XO. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 1: 347-57. PMID 10933953 DOI: 10.1006/mthe.2000.0046  0.96
2000 Klein C, Kann M, Kis B, Pramstaller PP, Breakefield XO, Ozelius LJ, Vieregge P. [Genetics of dystonia]. Der Nervenarzt. 71: 431-41. PMID 10919137 DOI: 10.1007/s001150050604  0.96
2000 Herrlinger U, Jacobs A, Quinones A, Woiciechowsky C, Sena-Esteves M, Rainov NG, Fraefel C, Breakefield XO. Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma. Human Gene Therapy. 11: 1429-38. PMID 10910140 DOI: 10.1089/10430340050057503  0.96
2000 Sena-Esteves M, Saeki Y, Fraefel C, Breakefield XO. HSV-1 amplicon vectors--simplicity and versatility. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 9-15. PMID 10899823 DOI: 10.1006/mthe.2000.0096  0.96
2000 Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. The Journal of Gene Medicine. 2: 148-64. PMID 10894261 DOI: 10.1002/(SICI)1521-2254(200005/06)2:3<148::AID-JGM105>3.0.CO;2-Q  0.96
2000 Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J, Woodward H, Castellan CC, Scherer M, Vieregge P, Breakefield XO, Kramer PL, Ozelius LJ. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Annals of Neurology. 48: 65-71. PMID 10894217 DOI: 10.1002/1531-8249(200007)48:1<65::AID-ANA10>3.0.CO;2-L  0.96
2000 Bearer EL, Breakefield XO, Schuback D, Reese TS, LaVail JH. Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument. Proceedings of the National Academy of Sciences of the United States of America. 97: 8146-50. PMID 10884436 DOI: 10.1073/pnas.97.14.8146  0.96
2000 Hewett J, Gonzalez-Agosti C, Slater D, Ziefer P, Li S, Bergeron D, Jacoby DJ, Ozelius LJ, Ramesh V, Breakefield XO. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Human Molecular Genetics. 9: 1403-13. PMID 10814722  0.96
2000 Sena-Esteves M, Camp SM, Alroy J, Breakefield XO, Kaye EM. Correction of acid beta-galactosidase deficiency in GM1 gangliosidosis human fibroblasts by retrovirus vector-mediated gene transfer: higher efficiency of release and cross-correction by the murine enzyme. Human Gene Therapy. 11: 715-27. PMID 10757351 DOI: 10.1089/10430340050015617  0.96
2000 Klein C, Gurvich N, Sena-Esteves M, Bressman S, Brin MF, Ebersole BJ, Fink S, Forsgren L, Friedman J, Grimes D, Holmgren G, Kyllerman M, Lang AE, de Leon D, Leung J, ... ... Breakefield XO, et al. Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia. Annals of Neurology. 47: 369-73. PMID 10716258 DOI: 10.1002/1531-8249(200003)47:3<369::AID-ANA14>3.0.CO;2-9  0.96
2000 Costantini LC, Bakowska JC, Breakefield XO, Isacson O. Gene therapy in the CNS. Gene Therapy. 7: 93-109. PMID 10673714 DOI: 10.1038/sj.gt.3301119  0.96
1999 Klein C, Breakefield XO, Ozelius LJ. Genetics of primary dystonia. Seminars in Neurology. 19: 271-80. PMID 12194383 DOI: 10.1055/s-2008-1040843  0.96
1999 Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia (New York, N.Y.). 1: 402-16. PMID 10933055  0.96
1999 Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis. Neoplasia (New York, N.Y.). 1: 387-401. PMID 10933054  0.96
1999 Jacobs A, Dubrovin M, Hewett J, Sena-Esteves M, Tan CW, Slack M, Sadelain M, Breakefield XO, Tjuvajev JG. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia (New York, N.Y.). 1: 154-61. PMID 10933050  0.96
1999 Pechan PA, Herrlinger U, Aghi M, Jacobs A, Breakefield XO. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. The Journal of Gene Medicine. 1: 176-85. PMID 10738566 DOI: 10.1002/(SICI)1521-2254(199905/06)1:3<176::AID-JGM35>3.0.CO;2-T  0.96
1999 Ozelius LJ, Page CE, Klein C, Hewett JW, Mineta M, Leung J, Shalish C, Bressman SB, de Leon D, Brin MF, Fahn S, Corey DP, Breakefield XO. The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics. 62: 377-84. PMID 10644435 DOI: 10.1006/geno.1999.6039  0.96
1999 Klein C, Friedman J, Bressman S, Vieregge P, Brin MF, Pramstaller PP, De Leon D, Hagenah J, Sieberer M, Fleet C, Kiely R, Xin W, Breakefield XO, Ozelius LJ, Sims KB. Genetic testing for early-onset torsion dystonia (DYT1): introduction of a simple screening method, experiences from testing of a large patient cohort, and ethical aspects. Genetic Testing. 3: 323-8. PMID 10627938  0.96
1999 Jansen G, Peters GJ, Pinedo HM, Priest DG, Assaraf YG, Aghi M, Kramm CM, Breakefield XO, Sirotnak FM. Re: Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo [2] Journal of the National Cancer Institute. 91: 2047-2050. PMID 10580033  0.96
1999 Bearer EL, Schlief ML, Breakefield XO, Schuback DE, Reese TS, LaVail JH. Squid axoplasm supports the retrograde axonal transport of herpes simplex virus. The Biological Bulletin. 197: 257-8. PMID 10573844  0.96
1999 Sena-Esteves M, Saeki Y, Camp SM, Chiocca EA, Breakefield XO. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. Journal of Virology. 73: 10426-39. PMID 10559361  0.96
1999 Augood SJ, Martin DM, Ozelius LJ, Breakefield XO, Penney JB, Standaert DG. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Annals of Neurology. 46: 761-9. PMID 10553994 DOI: 10.1002/1531-8249(199911)46:5<761::AID-ANA12>3.0.CO;2-Z  0.96
1999 Rainov NG, Ikeda K, Qureshi N, Grover S, Barnett FH, Herrlinger U, Quinones A, Chiocca EA, Breakefield XO. Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors. Frontiers of Radiation Therapy and Oncology. 33: 227-40. PMID 10549492  0.96
1999 Costantini LC, Jacoby DR, Wang S, Fraefel C, Breakefield XO, Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Human Gene Therapy. 10: 2481-94. PMID 10543613 DOI: 10.1089/10430349950016825  0.96
1999 Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Research. 59: 3861-5. PMID 10463570  0.96
1999 Derby ML, Sena-Esteves M, Breakefield XO, Corey DP. Gene transfer into the mammalian inner ear using HSV-1 and vaccinia virus vectors. Hearing Research. 134: 1-8. PMID 10452370 DOI: 10.1016/S0378-5955(99)00045-3  0.96
1999 Kramer PL, Mineta M, Klein C, Schilling K, de Leon D, Farlow MR, Breakefield XO, Bressman SB, Dobyns WB, Ozelius LJ, Brashear A. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. Annals of Neurology. 46: 176-82. PMID 10443882 DOI: 10.1002/1531-8249(199908)46:2<176::AID-ANA6>3.0.CO;2-2  0.96
1999 Aghi M, Kramm CM, Breakefield XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. Journal of the National Cancer Institute. 91: 1233-41. PMID 10413425  0.96
1999 Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, Doheny D, Bressman S, Fahn S, Breakefield XO, Ozelius LJ. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proceedings of the National Academy of Sciences of the United States of America. 96: 5173-6. PMID 10220438 DOI: 10.1073/pnas.96.9.5173  0.96
1999 Barnett FH, Rainov NG, Ikeda K, Schuback DE, Elliott P, Kramm CM, Chase M, Qureshi NH, Harsh G, Chiocca EA, Breakefield XO. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Therapy. 6: 14-20. PMID 10078959 DOI: 10.1038/sj.cgt.7700003  0.96
1999 Schuback DE, Mulligan EL, Sims KB, Tivol EA, Greenberg BD, Chang SF, Yang SL, Mau YC, Shen CY, Ho MS, Yang NH, Butler MG, Fink S, Schwartz CE, Berlin F, ... Breakefield XO, et al. Screen for MAOA mutations in target human groups. American Journal of Medical Genetics. 88: 25-8. PMID 10050962 DOI: 10.1002/(SICI)1096-8628(19990205)88:1<25::AID-AJMG4>3.0.CO;2-E  0.96
1999 Klein C, Page CE, LeWitt P, Gordon MF, de Leon D, Awaad Y, Breakefield XO, Brin MF, Ozelius LJ. Genetic analysis of three patients with an 18p- syndrome and dystonia. Neurology. 52: 649-51. PMID 10025808  0.96
1998 Rainov NG, Sena-Esteves M, Fraefel C, Dobberstein KU, Chiocca EA, Breakefield XO. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma. Advances in Experimental Medicine and Biology. 451: 393-403. PMID 10026902  0.44
1998 Klein C, Vieregge P, Heide W, Kemper B, Hagedorn-Greiwe M, Hagenah J, Vollmer C, Breakefield XO, Kömpf D, Ozelius L. Exclusion of chromosome regions 6p12 and 15q11, but not chromosome region 7p11, in a German family with autosomal dominant congenital nystagmus. Genomics. 54: 176-7. PMID 9806847 DOI: 10.1006/geno.1998.5535  0.96
1998 Brashear A, Butler IJ, Ozelius LJ, Kramer PI, Farlow MR, Breakefield XO, Dobyns WB. Rapid-onset dystonia-parkinsonism: a report of clinical, biochemical, and genetic studies in two families. Advances in Neurology. 78: 335-9. PMID 9750930  0.96
1998 Bressman SB, de Leon D, Raymond D, Greene PE, Brin MF, Fahn S, Ozelius LJ, Breakefield XO, Kramer PL, Risch NJ. The role of the DYT1 gene in secondary dystonia. Advances in Neurology. 78: 107-15. PMID 9750907  0.96
1998 Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Jacoby D, Penney J, Risch NJ, Fahn S, Gusella JF, Breakefield XO. The gene (DYT1) for early-onset torsion dystonia encodes a novel protein related to the Clp protease/heat shock family. Advances in Neurology. 78: 93-105. PMID 9750906  0.96
1998 Bressman SB, de Leon D, Raymond D, Ozelius LJ, Breakefield XO, Nygaard TG, Almasy L, Risch NJ, Kramer PL. Clinical-genetic spectrum of primary dystonia. Advances in Neurology. 78: 79-91. PMID 9750905  0.96
1998 Klein C, Pramstaller PP, Castellan CC, Breakefield XO, Kramer PL, Ozelius LJ. Clinical and genetic evaluation of a family with a mixed dystonia phenotype from South Tyrol. Annals of Neurology. 44: 394-8. PMID 9749609 DOI: 10.1002/ana.410440318  0.96
1998 Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, Pechan PA, Barth RF, Finkelstein D, Chiocca EA, Louis DN, Breakefield XO. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Therapy. 5: 809-19. PMID 9747461 DOI: 10.1038/sj.gt.3300643  0.96
1998 Rainov NG, Dobberstein KU, Sena-Esteves M, Herrlinger U, Kramm CM, Philpot RM, Hilton J, Chiocca EA, Breakefield XO. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol. Human Gene Therapy. 9: 1261-73. PMID 9650611 DOI: 10.1089/hum.1998.9.9-1261  0.96
1998 Augood SJ, Penney JB, Friberg IK, Breakefield XO, Young AB, Ozelius LJ, Standaert DG. Expression of the early-onset torsion dystonia gene (DYT1) in human brain. Annals of Neurology. 43: 669-73. PMID 9585364 DOI: 10.1002/ana.410430518  0.96
1998 Murphy DL, Sims K, Eisenhofer G, Greenberg BD, George T, Berlin F, Zametkin A, Ernst M, Breakefield XO. Are MAO-A deficiency states in the general population and in putative high-risk populations highly uncommon? Journal of Neural Transmission. Supplementum. 52: 29-38. PMID 9564605  0.96
1997 Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA. Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors. Molecular Medicine (Cambridge, Mass.). 3: 813-25. PMID 9440115  0.96
1997 Aboody-Guterman KS, Pechan PA, Rainov NG, Sena-Esteves M, Jacobs A, Snyder EY, Wild P, Schraner E, Tobler K, Breakefield XO, Fraefel C. Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo. Neuroreport. 8: 3801-8. PMID 9427374  0.96
1997 Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Human Gene Therapy. 8: 2057-68. PMID 9414254 DOI: 10.1089/hum.1997.8.17-2057  0.44
1997 Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakefield XO, Yu JS. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Therapy. 4: 345-52. PMID 9408604  0.96
1997 Isacson O, Breakefield XO. Benefits and risks of hosting animal cells in the human brain. Nature Medicine. 3: 964-9. PMID 9288721 DOI: 10.1038/nm0997-964  0.96
1997 Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, de Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nature Genetics. 17: 40-8. PMID 9288096 DOI: 10.1038/ng0997-40  0.96
1997 Paulus W, Baur I, Oberer DM, Breakefield XO, Reeves SA. Regulated expression of the diphtheria toxin A gene in human glioma cells using prokaryotic transcriptional control elements. Journal of Neurosurgery. 87: 89-95. PMID 9202271 DOI: 10.3171/jns.1997.87.1.0089  0.96
1997 Bressman SB, de Leon D, Raymond D, Greene PE, Brin MF, Fahn S, Ozelius LJ, Breakefield XO, Kramer PL, Risch NJ. Secondary dystonia and the DYTI gene. Neurology. 48: 1571-7. PMID 9191768  0.96
1997 Rage F, Hill DF, Sena-Esteves M, Breakefield XO, Coffey RJ, Costa ME, McCann SM, Ojeda SR. Targeting transforming growth factor alpha expression to discrete loci of the neuroendocrine brain induces female sexual precocity. Proceedings of the National Academy of Sciences of the United States of America. 94: 2735-40. PMID 9122266 DOI: 10.1073/pnas.94.6.2735  0.96
1997 Johnston KM, Jacoby D, Pechan PA, Fraefel C, Borghesani P, Schuback D, Dunn RJ, Smith FI, Breakefield XO. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Human Gene Therapy. 8: 359-70. PMID 9048203 DOI: 10.1089/hum.1997.8.3-359  0.96
1996 Yu JS, Sena-Esteves M, Paulus W, Breakefield XO, Reeves SA. Retroviral delivery and tetracycline-dependent expression of IL-1beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells. Cancer Research. 56: 5423-7. PMID 8968096  0.96
1996 Pechan PA, Fotaki M, Thompson RL, Dunn R, Chase M, Chiocca EA, Breakefield XO. A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors. Human Gene Therapy. 7: 2003-13. PMID 8930661 DOI: 10.1089/hum.1996.7.16-2003  0.96
1996 Kramm CM, Rainov NG, Sena-Esteves M, Barnett FH, Chase M, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment. Human Gene Therapy. 7: 1989-94. PMID 8930659 DOI: 10.1089/hum.1996.7.16-1989  0.44
1996 Kramm CM, Rainov NG, Sena-Esteves M, Chase M, Pechan PA, Chiocca EA, Breakefield XO. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Human Gene Therapy. 7: 291-300. PMID 8835217 DOI: 10.1089/hum.1996.7.3-291  0.44
1996 Paulus W, Baur I, Boyce FM, Breakefield XO, Reeves SA. Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells. Journal of Virology. 70: 62-7. PMID 8523582  0.96
1995 Isacson O, Frim DM, Galpern WR, Tatter SB, Breakefield XO, Schumacher JM. Cell-mediated delivery of neurotrophic factors and neuroprotection in the neostriatum and substantia nigra. Restorative Neurology and Neuroscience. 8: 59-61. PMID 21551807 DOI: 10.3233/RNN-1995-81213  0.96
1995 Wei MX, Tamiya T, Rhee RJ, Breakefield XO, Chiocca EA. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 1: 1171-7. PMID 9815909  0.96
1995 Kramm CM, Sena-Esteves M, Barnett FH, Rainov NG, Schuback DE, Yu JS, Pechan PA, Paulus W, Chiocca EA, Breakefield XO. Gene therapy for brain tumors. Brain Pathology (Zurich, Switzerland). 5: 345-81. PMID 8974620  0.44
1995 Tamiya T, Wei MX, Chase M, Ono Y, Lee F, Breakefield XO, Chiocca EA. Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells. Gene Therapy. 2: 531-8. PMID 8593603  0.96
1995 Yoshimoto Y, Lin Q, Collier TJ, Frim DM, Breakefield XO, Bohn MC. Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease. Brain Research. 691: 25-36. PMID 8590062 DOI: 10.1016/0006-8993(95)00596-I  0.96
1995 Blumenfeld A, Lucente DE, Trofatter JA, Lerner T, Slaugenhaupt SA, Liebert CB, Monahan M, Haines JL, Gusella JF, Breakefield XO, Parysek LM. Peripherin gene is linked to keratin 18 gene on human chromosome 12. Somatic Cell and Molecular Genetics. 21: 83-8. PMID 7541564 DOI: 10.1007/BF02255825  0.96
1994 Davar G, Kramer MF, Garber D, Roca AL, Andersen JK, Bebrin W, Coen DM, Kosz-Vnenchak M, Knipe DM, Breakefield XO. Gene transfer to sensory neurons using herpes virus vectors. Gene Therapy. 1: S24. PMID 8542387  0.96
1994 Corey DP, Breakefield XO. Transcription factors in inner ear development. Proceedings of the National Academy of Sciences of the United States of America. 91: 433-6. PMID 8290543  0.96
1994 Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proceedings of the National Academy of Sciences of the United States of America. 91: 5104-8. PMID 8197193 DOI: 10.1073/pnas.91.11.5104  0.96
1994 Davar G, Kramer MF, Garber D, Roca AL, Andersen JK, Bebrin W, Coen DM, Kosz-Vnenchak M, Knipe DM, Breakefield XO. Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors. The Journal of Comparative Neurology. 339: 3-11. PMID 8106660 DOI: 10.1002/cne.903390103  0.96
1994 Castillo B, del Cerro M, Breakefield XO, Frim DM, Barnstable CJ, Dean DO, Bohn MC. Retinal ganglion cell survival is promoted by genetically modified astrocytes designed to secrete brain-derived neurotrophic factor (BDNF). Brain Research. 647: 30-6. PMID 8069702 DOI: 10.1016/0006-8993(94)91395-1  0.96
1994 Bressman SB, de Leon D, Kramer PL, Ozelius LJ, Brin MF, Greene PE, Fahn S, Breakefield XO, Risch NJ. Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Annals of Neurology. 36: 771-7. PMID 7979224 DOI: 10.1002/ana.410360514  0.96
1994 Boviatsis EJ, Park JS, Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO, Chiocca EA. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Research. 54: 5745-51. PMID 7954393  0.44
1994 Cunningham LA, Short MP, Breakefield XO, Bohn MC. Nerve growth factor released by transgenic astrocytes enhances the function of adrenal chromaffin cell grafts in a rat model of Parkinson's disease. Brain Research. 658: 219-31. PMID 7834345  0.96
1994 Andersen JK, Frim DM, Isacson O, Beal MF, Breakefield XO. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Research. 656: 108-14. PMID 7804823 DOI: 10.1016/0006-8993(94)91371-4  0.96
1994 Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Therapy. 1: 323-31. PMID 7584098  0.96
1993 Yan W, Boustany RM, Konradi C, Ozelius L, Lerner T, Trofatter JA, Julier C, Breakefield XO, Gusella JF, Haines JL. Localization of juvenile, but not late-infantile, neuronal ceroid lipofuscinosis on chromosome 16. American Journal of Human Genetics. 52: 89-95. PMID 8434611  0.96
1993 Frim DM, Short MP, Rosenberg WS, Simpson J, Breakefield XO, Isacson O. Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. Journal of Neurosurgery. 78: 267-73. PMID 8421209 DOI: 10.3171/jns.1993.78.2.0267  0.96
1993 Takamiya Y, Short MP, Moolten FL, Fleet C, Mineta T, Breakefield XO, Martuza RL. An experimental model of retrovirus gene therapy for malignant brain tumors. Journal of Neurosurgery. 79: 104-10. PMID 8391069 DOI: 10.3171/jns.1993.79.1.0104  0.96
1993 Hoffman D, Breakefield XO, Short MP, Aebischer P. Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Experimental Neurology. 122: 100-6. PMID 8339781 DOI: 10.1006/exnr.1993.1111  0.96
1993 Chen ZY, Battinelli EM, Hendriks RW, Powell JF, Middleton-Price H, Sims KB, Breakefield XO, Craig IW. Norrie disease gene: characterization of deletions and possible function. Genomics. 16: 533-5. PMID 8314592 DOI: 10.1006/geno.1993.1224  0.96
1993 Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarskis EJ, Butler IJ, Breakefield XO. Rapid-onset dystonia-parkinsonism. Neurology. 43: 2596-602. PMID 8255463  0.96
1993 Andersen JK, Frim DM, Isacson O, Breakefield XO. Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cellular and Molecular Neurobiology. 13: 503-15. PMID 8111822 DOI: 10.1007/BF00711459  0.96
1993 Frim DM, Simpson J, Uhler TA, Short MP, Bossi SR, Breakefield XO, Isacson O. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. Journal of Neuroscience Research. 35: 452-8. PMID 8103116 DOI: 10.1002/jnr.490350413  0.96
1993 Frim DM, Uhler TA, Short MP, Ezzedine ZD, Klagsbrun M, Breakefield XO, Isacson O. Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport. 4: 367-70. PMID 8098961  0.96
1992 Konradi C, Ozelius L, Breakefield XO. Highly polymorphic (GT)n repeat sequence in intron II of the human MAOB gene. Genomics. 12: 176-7. PMID 1733859 DOI: 10.1016/0888-7543(92)90426-S  0.96
1992 Andersen JK, Herrup K, Breakefield XO. Creation of transgenic mice that overexpress monoamine oxidase-B neuronally. Annals of the New York Academy of Sciences. 648: 241-3. PMID 1637050 DOI: 10.1111/j.1749-6632.1992.tb24544.x  0.96
1992 Girmen AS, Baenziger J, Hotamisligil GS, Konradi C, Shalish C, Sullivan JL, Breakefield XO. Relationship between platelet monoamine oxidase B activity and alleles at the MAOB locus. Journal of Neurochemistry. 59: 2063-6. PMID 1431894  0.96
1992 Chen ZY, Powell JF, Hsu YP, Breakefield XO, Craig IW. Organization of the human monoamine oxidase genes and long-range physical mapping around them. Genomics. 14: 75-82. PMID 1427833 DOI: 10.1016/S0888-7543(05)80286-1  0.96
1992 Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza RL. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells. Journal of Neuroscience Research. 33: 493-503. PMID 1335091 DOI: 10.1002/jnr.490330316  0.96
1992 Andersen JK, Garber DA, Meaney CA, Breakefield XO. Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter. Human Gene Therapy. 3: 487-99. PMID 1329993 DOI: 10.1089/hum.1992.3.5-487  0.96
1992 Huang Q, Vonsattel JP, Schaffer PA, Martuza RL, Breakefield XO, DiFiglia M. Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study. Experimental Neurology. 115: 303-16. PMID 1311266 DOI: 10.1016/0014-4886(92)90196-W  0.96
1992 Chen ZY, Hendriks RW, Jobling MA, Powell JF, Breakefield XO, Sims KB, Craig IW. Isolation and characterization of a candidate gene for Norrie disease. Nature Genetics. 1: 204-8. PMID 1303236 DOI: 10.1038/ng0692-204  0.96
1992 Titlow CC, Andersen JK, Trofatter JA, Breakefield XO. In vitro translation of proteins with terminal deletions by SP6 RNA polymerase-mediated transcription of PCR products. Pcr Methods and Applications. 2: 172-4. PMID 1282438  0.96
1991 Konradi C, Ozelius L, Yan W, Gusella JF, Breakefield XO. Dinucleotide repeat polymorphism (D16S285) on human chromosome 16. Nucleic Acids Research. 19: 5449. PMID 1923837  0.96
1991 Chen ZY, Hotamisligil GS, Huang JK, Wen L, Ezzeddine D, Aydin-Muderrisoglu N, Powell JF, Huang RH, Breakefield XO, Craig I. Structure of the human gene for monoamine oxidase type A. Nucleic Acids Research. 19: 4537-41. PMID 1886775 DOI: 10.1093/nar/19.16.4537  0.96
1991 Kwiatkowski DJ, Ozelius L, Kramer PL, Perman S, Schuback DE, Gusella JF, Fahn S, Breakefield XO. Torsion dystonia genes in two populations confined to a small region on chromosome 9q32-34. American Journal of Human Genetics. 49: 366-71. PMID 1867195  0.96
1991 Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. American Journal of Human Genetics. 49: 383-92. PMID 1678250  0.96
1991 Cunningham LA, Short MP, Vielkind U, Breakefield XO, Bohn MC. Survival and differentiation within the adult mouse striatum of grafted rat pheochromocytoma cells (PC12) genetically modified to express recombinant beta-NGF. Experimental Neurology. 112: 174-82. PMID 1674694 DOI: 10.1016/0014-4886(91)90067-M  0.96
1991 Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, Breakefield XO. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. The New Biologist. 3: 608-14. PMID 1655012  0.96
1991 Breakefield XO, DeLuca NA. Herpes simplex virus for gene delivery to neurons. The New Biologist. 3: 203-18. PMID 1652278  0.96
1974 Breakefield XO, Nirenberg MW. Selection for neuroblastoma cells that synthesize certain transmitters. Proceedings of the National Academy of Sciences of the United States of America. 71: 2530-3. PMID 4152249  0.96
Show low-probability matches.